HC Wainwright restated their buy rating on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH – Free Report) (TSE:AUP) in a research note released on Friday morning, Benzinga reports. The brokerage currently has a $15.00 target price on the biotechnology company’s stock. Separately, StockNews.com assumed coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, August 17th. […]